Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma

Kohei Shitara, Mustafa Özgüroğlu, Y.-J. Bang, Maria Di Bartolomeo, Mario Mandalà, M.-H. Ryu, Christian Caglevic, Hyun Cheol Chung, Kei Muro, Eric Van Cutsem, Julie Kobie, Răzvan Cristescu, Deepti Aurora-Garg, Lu Jia, C.-S. Shih, David E. Adelberg, Z. Alexander Cao, Charles S. Fuchs